Asthma Therapy Tablet, Orally Disintegrating
NDC Package 17312-017-14
Package Information
Asthma Therapy (arsenic trioxide - histamine dihydrochloride - dermatophagoides pteronyssinus - magnesium phosphate, dibasic trihydrate - strychnos nux-vomica seed - aspidosperma quebracho-blanco bark - suplhur -) tablets is suitable for adults and children 12 years and above.Dissolve entire tablet under tongue.Do not chew or swallow whole.Take 1 tablet 3 times a day or as directed by a physician.Use up to 6 times a day as needed.Take at least 10 minutes before or at least 10 minutes after eating or drinking.Children under the age of 12: consult a physician before use. This formulation utilizes a tablet, orally disintegrating delivery system. Marketed by Trp Company, this product is identified by NDC 17312-017.
Identification & Billing
Clinical Specifications
- Allergens - [CS]
- Allergens - [CS]
- Antigens, Dermatophagoides - [CS]
- Calculi Dissolution Agent - [EPC] (Established Pharmacologic Class)
- Cell-mediated Immunity - [PE] (Physiologic Effect)
- Increased Histamine Release - [PE] (Physiologic Effect)
- Increased IgG Production - [PE] (Physiologic Effect)
- Increased Large Intestinal Motility - [PE] (Physiologic Effect)
- Inhibition Large Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Inhibition Small Intestine Fluid/Electrolyte Absorption - [PE] (Physiologic Effect)
- Insect Proteins - [CS]
- Magnesium Ion Exchange Activity - [MoA] (Mechanism of Action)
- Non-Standardized Plant Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Osmotic Activity - [MoA] (Mechanism of Action)
- Osmotic Laxative - [EPC] (Established Pharmacologic Class)
- Plant Proteins - [CS]
- Seed Storage Proteins - [CS]
- Standardized Insect Allergenic Extract - [EPC] (Established Pharmacologic Class)
- Stimulation Large Intestine Fluid/Electrolyte Secretion - [PE] (Physiologic Effect)
Regulatory & Marketing
Hierarchy Structure
- 17312 - Trp Company
- 17312-017 - Asthma Therapy
- 17312-017-14 - 1 BOTTLE in 1 PACKAGE / 70 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE
- 17312-017 - Asthma Therapy
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 17312-017-14 identifies a specific commercial package of 1 bottle in 1 package / 70 tablet, orally disintegrating in 1 bottle of Asthma Therapy, a human over the counter drug labeled by Trp Company. This tablet, orally disintegrating is formulated for oral use and contains arsenic trioxide; aspidosperma quebracho-blanco bark; dermatophagoides pteronyssinus; histamine dihydrochloride; magnesium phosphate, dibasic trihydrate; strychnos nux-vomica seed; sulfur as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Trp Company on December 01, 2011. The current certification is valid through December 31, 2026.
How is this Trp Company product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 17312001714. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.